Table 1. Demographics for control subjects and patients with SCD with and without chronic pain.
| Sickle Cell Disease | Control Group | Sickle Cell Disease- Pain phenotype | ||||
|---|---|---|---|---|---|---|
| Demographics | Overall (n = 22) | No chronic pain (n = 10) | P-value | Chronic pain (n = 15) | No chronic pain (n = 7) | P-value |
| Age, years, median (IQR) | 28 (25–37) | 31 (24–41) | 0.7 | 31.4 (26–43) | 24.1 (21–27) | 0.002 |
| Gender, n (% female) | 13 (59) | 5 (50) | 0.7 | 10 (67) | 3 (43) | 0.4 |
| SCD genotype (n, %) | ||||||
| HbSS | 17 (77) | NA | NA | 10 (67) | 7 (100) | 0.4 |
| HbSC | 4 (18) | 4 (27) | 0 (0) | |||
| HbSbthal0 | 1 (5) | 1 (7) | 0 (0) | |||
| Hydroxyurea use, n (% yes) | 8 (36) | NA | NA | 7 (47) | 1 (14) | 0.2 |
| Baseline Labs, median (IQR) | ||||||
| WBC (#/ul) | 9.1 (5.6–10.9) | 6.3 (4.7–8.3) | 0.08 | 9.1 (5.3–10.5) | 8.2 (5.7–12.1) | 0.9 |
| Hgb (g/dl) | 9.3 (8.5–10.5) | 13.8 (11.8–15.8) | <0.0001 | 9.5 (9.1–10.6) | 8.5 (8.2–9.1) | 0.01 |
| reticulocyte percent (%) | 7.0 (5.5–14.0) | 1.5 (1.2–1.8) | <0.0001 | 7.0 (4.8–12.6) | 6.9 (5.9–17.6) | 0.5 |
| Hospital Utilization (median number over last 3 years) | ||||||
| Unscheduled Clinic Visit | 1.5 (0–8.3) | NA | NA | 1 (0–13) | 2 (1–6) | 0.8 |
| ED Visit | 3 (1–6.3) | NA | NA | 3 (1–8) | 4 (1–5) | 0.8 |
| Inpatient Hospitalization | 3 (1.8–6) | NA | NA | 3 (1–6) | 3 (2–6) | 0.8 |
| Morphine milligram equivalent (mg), median (IQR) | 72.3 (50.3–240) | NA | NA | 190.7 (72.3–317.1) | 33.7 (6.7–62.1) | 0.002 |